CNBX Pharmaceuticals Inc. (CNBX) stock
Close on Oct 19, 2026Market cap $197.79KP/E –Yield –
CNBX Pharmaceuticals Inc. reported revenue of $0 for the twelve months to May 31, 2026. At the latest close the market valued the company at $197.79K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at May 31, 2026
Valuation
- Market cap
- $197.79K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$462.09K
- EPS, diluted
- $0.00
- Book value per share
- -$0.00
- Diluted shares
- 1.32B
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 533,554
- Average volume (20 days)
- 6,889,274
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNBX | S&P 500 | Difference | CNBX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +42.9% | +0.6% | +42.2 pts | ||
| 3 months | +50.0% | +3.4% | +46.6 pts | ||
| Year to date | -62.5% | +13.3% | −75.8 pts | ||
| 1 year | -70.0% | +16.6% | −86.6 pts | ||
| 3 years | -99.0% | +86.4% | −185.4 pts | -78.7% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.9 pts | -90.2% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -69.1% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases CNBX Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
About CNBX Pharmaceuticals
Pharmaceutical Preparations
CNBX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based products and technologies for cancer treatment. Its development pipeline includes Cannabics SR, an oral capsule designed to treat advanced cancer and cancer anorexia-cachexia syndrome. The company is also developing RCC-33, a synthetic cannabinoid candidate targeting colorectal cancer as a neoadjuvant therapy before cancer staging or as an adjuvant therapy following colonoscopy. CNBX focuses on drug discovery, intellectual property protection, and regulatory approval pathways, without conducting manufacturing, distribution, or commercial sales.
Company profile, executives and historyCNBX Pharmaceuticals stock: common questions
What is CNBX Pharmaceuticals's stock price?
CNBX closed at $0.00 on Oct 19, 2026, up 0.00% on the day.
What is CNBX Pharmaceuticals's market cap?
CNBX Pharmaceuticals was worth $197.79K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CNBX's P/E ratio?
CNBX Pharmaceuticals lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does CNBX Pharmaceuticals make?
CNBX Pharmaceuticals reported revenue of $0 for the twelve months to May 31, 2026.
Does CNBX Pharmaceuticals pay a dividend?
No. CNBX Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has CNBX stock performed over the past year?
Including dividends, CNBX returned -70.0% over the past year, against +16.6% for the S&P 500.
Who are CNBX Pharmaceuticals's competitors?
Companies most similar to CNBX Pharmaceuticals by business, industry and size include KZIA, NTHI, IXHL, ADXN, IBO.
See a number that looks wrong?